I
nflammatory bowel disease is a chronic inflammatory disorder of the intestine consisting mainly of ulcerative colitis (UC) and Crohn's disease (CD). The inflammatory disease, microscopic colitis (MC), comprises collagenous colitis (CC) and lymphocytic colitis (LC), and is characterized clinically by symptoms such as chronic watery diarrhea, abdominal pain, and weight loss. 1 In contrast to UC, the colonic mucosa in MC appears endoscopically normal or near normal, although typical changes are detected on microscopic examination. T-cell infiltration in the mucosa plays a major role in MC immunopathology. CD8 + intraepithelial lymphocyte (IEL) infiltration was detected in both CC and LC patients with the most notable increase in patients with LC. [2] [3] [4] [5] In contrast, the amount of CD4 + T cells was reduced in the lamina propria of both patients with CC and LC. 4 Moreover, we have previously demonstrated an expansion of local resident T cells rather than direct recruitment of recent thymic emigrants to the mucosa based on reduced levels of T-cell receptor (TCR) excision circles in the mucosa of both patients with CC and LC. 6 The molecular basis for the immune activation in the colon of patients with MC is poorly understood and not very much is known about what the immune responses are directed toward. Antigens are presented by major histocompatibility complex molecules to the membrane-bound TCRs consisting of either an ab or a gd heterodimer. 7 The TCR antigen specificity and diversity are primarily determined by amino acid sequences encoded in the CDR3 (third complementarity determining region) variable recombination event of multiple randomly selected variable (V) b, diversity (D) b, and joining (J) b gene segments for the TCRb chain as well as Va and Ja gene segments for the TCRa chain. With the addition and deletion of individual nucleotides at the junctional sites (N-region additions), the chain diversity is further increased. 8 Previous studies focusing on the TCR repertoire have shown oligoclonal expansion of T cells in the noninflamed mucosa of patients with CD. [9] [10] [11] According to previous findings, patients with CD display decreased diversity of their TCR repertoire as compared to noninflamed tissue of the same patient as measured by CDR3 length analysis using PCR, 11, 12 immunofluorescence, 13 or flow cytometry, 14 as well as compared with healthy controls using CDR3 length analysis through PCR. 15 Furthermore, patients with CD express certain TCR clones, although there are some variations in types in different studies. [11] [12] [13] [14] [15] [16] Similarly, studies focused on patients with UC showed specific TCR clones compared with noninflamed controls, inflammatory controls, or healthy controls using CDR3 length analysis through PCR. [17] [18] [19] [20] However, to the best of our knowledge, there is hitherto no study investigating T-cell repertoires in patients with MC, nor in patients with UC through screening for all known TCRbV and J segments using high-throughput sequencing. Our aim of this study was to investigate the regional diversity of the TCRb repertoire at the level of TRBV-J element combinations using targeted next-generation sequencing (NGS) in colonic biopsies of patients with MC, as well as UC compared with noninflamed controls.
Our results showed differences in diversities of TCRb clone distributions between patients with CC and LC, supporting the hypothesis that CC and LC are 2 different entities. Patients with UC and UC-R also showed differences in diversity of their clone distributions. In addition, based on both univariate and multivariate analyses, we detected TRBV-J clones differentially expressed between the investigated disease types. These results contribute to the knowledge of MC immunopathology by suggesting selective T-cell expansion.
MATERIALS AND METHODS

Patient Data
Colonic mucosal biopsies were collected from a total of 26 patients with CC, 15 with LC, and 33 with UC, as well as 35 controls. Patients with a previous history of CD, gastrointestinal infection, ischemic colitis, colorectal cancer, or treatment with immunosuppressive drugs or antibiotics were excluded after endoscopic observations, small bowel imaging, and histopathological examinations.
MC
Patients with MC underwent colonoscopy because of symptoms such as watery diarrhea, abdominal pain, and weight loss. Routine biopsy specimens were obtained from the proximal, transverse, and distal colon for confirmation of diagnosis through histopathological examination of paraffin-embedded slides by an experienced gastropathologist (Agnes Hegedus, Department of Pathology, Örebro University Hospital). Histopathological criteria for CC were a diffusely distributed and thickened subepithelial collagen layer ($10 mm) in comparison with 0 to 3 mm in healthy individuals. 21 As the subepithelial collagen layer may vary through the colon, the biopsies taken from the proximal colon give more reliable results. 21 Diagnosis of LC was made through the presence of increased numbers of IELs, $ 20 IELs per 100 surface intestinal epithelial cells, whereas healthy individuals usually have ,5 IELs per 100 intestinal epithelial cells. 22 Increased numbers of IELs may be found in CC, but often less than in LC. In both CC and LC, mononuclear cell infiltration in the lamina propria is mainly by lymphocytes, but plasma cells, eosinophils, and neutrophils might be seen. 1 Both types of MC may show alterations in the epithelium such as flattening and vacuolization of the columnar cells, loss of mucin, and decreased numbers of goblet cells. 1, 23 Six patients with an established diagnosis of CC and 7 patients with LC no longer fulfilled the histopathological criteria for MC despite clinical symptoms of the disease. These patients were, therefore, categorized as clinically active but histopathologically in remission (CC-HR/LC-HR) 5 and were analyzed separately.
Three patients with CC, 1 patient with LC, and 2 patients with LC-HR were treated with budesonide at the time of colonoscopy, including 1 patient with CC having budesonide treatment only 3 days before the colonoscopy.
UC
The diagnosis of UC relied on well-established diagnostic criteria. 24 Endoscopic activity was assessed at colonoscopy and graded using the Mayo endoscopic subscore. 25 Based on this score, patients were categorized into 2 groups, with grade 0 representing endoscopic remission and grades 1 to 3 active disease. Fifteen patients had active UC, and 12 of them were treated with 5-aminosalicylic acid (5-ASA), as well as 1 patient with prednisolone at the time of colonoscopy. Nineteen patients, undergoing colonoscopy for colitis-associated cancer surveillance, were asymptomatic and had a Mayo Score of 0. Eleven of them were treated with 5-ASA, 1 patient with Salazopyrin, and the remaining 7 had no treatment at the time of colonoscopy.
Controls
Thirty-five control individuals underwent colonoscopy because of changes in bowel habits (4), weight loss (1), iron deficiency anemia (4), rectal bleeding (8), follow-up after diverticulitis (6), colon cancer screening (7), or abdominal pain (5) . The colonoscopies were macroscopically normal except for occasional diverticula in the left colon, and routine biopsy specimens from proximal, transverse, and distal colon revealed no pathological alterations.
At the time of the colonoscopy, 3 to 4 biopsies of 3 mm from patients with MC and controls were taken from the hepatic flexure, whereas biopsies from patients with UC were collected from endoscopically affected areas of the distal colon with standard biopsy forceps. The biopsies were immediately immersed in Allprotect Tissue Reagent (Qiagen, Hilden, Germany) and then stored at 2808C for further analysis. The clinical characteristics of patients and controls are summarized in Table 1 .
Ethical Considerations
Patients and controls were informed of the study protocol before colonoscopy, and gave their written consent to donate tissue samples for research purposes. The study was approved by the ethics committee of Örebro-Uppsala County (#2008/278).
Total RNA Isolation and Reverse Transcription
Total RNA was extracted from freshly collected mucosal biopsies using the GeneMATRIX RNA/miRNA Purification Kit (EURx, Berlin, Germany) following the manufacturer's instructions and was quantified using a NanoDrop 200 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE). cDNA transcription of 1 mg total RNA was performed by HighCapacity cDNA Reverse Transcription Kit (Applied Biosystems, Thermo Fisher Scientific, Austin, TX) based on the manufacturer's protocol.
Design of Degenerate Primers for TRBV
Seventy functional TCRb (TRBV) chain sequences were listed in the IMGT database (International ImMunoGeneTics information system, http://www.imgt.org/genedb/) in 2014. With the help of the biological sequence alignment editor, BioEdit v7.2.5 (Ibis Biosciences, Carlsbad, CA), all sequences were aligned to identify the regions with the highest similarity. The degenerate primers were designed to cover TRBV chains including the allelic variations according to suggestions by Zhou et al 26 and are summarized in Table 2 . The degenerate forward primer VP1 targeted 50 TRBV chains, whereas VP2 targeted 11 additional TRBV chains. 26 The primer VP3 was designed to detect for 4 TRBVs, whereas TRBV 14.1, not covered by any degenerate primers, was devised as VP4 separately. 26 Last, VP5 was designed to cover 4 TRBV chains. The specific reverse primers CP1 and CP2 were located in the C region of the TCR-b chain covering both C region alleles. 26 Moreover, Nextera transposon sequences were added to the forward primers from 5 0 (TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG) and to the reverse primers from 5 0 (GTCTCGTGGGCTCGGA-GATGTGTATAAGAGACAG) to enable and optimize their performance with Illumina instruments (Illumina Inc., San Diego, CA). All primers were ordered from Sigma-Aldrich (Steinheim, Germany).
cDNA samples were diluted 1:40 in nucleic acid-free water and were further amplified separately using 2 mM forward and 200 nM reverse primer combinations (VP1-CP1, VP1-CP2, ., VP5-CP2) with KAPA SYBR FAST qPCR for Bio-Rad iCycler (Kapa Biosystems, Boston, MA) according to the manufacturer's instructions in a GeneBio-Rad CFX96 Touch Real-Time PCR Detection System (Bio-Rad Laboratories Inc., Hercules, CA) including water samples as negative controls. Thereafter, PCR products (5 mL) were run on a 2% agarose gel (Sigma-Aldrich) to ensure the presence of PCR amplification.
Library Preparation
Amplified PCR products with degenerate primer pairs for each sample were pooled together. After PCR cleanup using Agencourt AMPure XP (Beckman Coulter Inc., Fullerton, CA), the samples were tagged with Nextera XT Index Primer 1 (N7xx, Illumina) and Nextera XT Index Primer 2 (S5xx, Illumina) using 2X KAPA HiFi HotStart Ready Mix (Kapa Biosystems) according to the manufacturer's instructions. Thereafter, indexed PCR products were cleaned up with Agencourt AMPure XP. Each indexed amplicon PCR (4 nM) was pooled according to calculations based on their average base sizes, as measured by Agilent High Sensitivity DNA Kit (Agilent Technologies, Santa Clara, CA) and their concentrations detected by Qubit dsDNA BR Assay Kit (Invitrogen, Thermo Fisher Scientific). Because the whole mucosal biopsies were used in this study to obtain the same concentration (45 nM) from each sample, we used the following formula: x 5 ðConcentration in ng=mLÞ=ð660 g=mol · average library sizeÞ. Thereby, the same sample size for each patient was used for NGS. These measurements were performed, and the PCR products were normalized according to instructions suggested by Illumina. Pooled samples, including a PhiX control, were denatured using 0.2 N NaOH and placed into a cartridge of Nextera XT MiSeq v3 600 cycles (Illumina). The deep sequencing was performed in a MiSeq desktop sequencer (Illumina) with default settings of paired end and adapter trimming.
Raw Data Analysis of NGS Data
Raw MiSeq sequence data were preprocessed using cutadapt 27 to eliminate adapter sequences still present in the raw sequence data and to filter out very small reads (minimum read length was set to 30 nucleotides). Afterward, the data were further analyzed using MiXCR software. 28 In a paired-end sequencing analysis, MiXCR aligned both reads and aggregated the information from both alignments based on reference Vb, Db, Jb, and Cb segments according to GenBank. 29 The software further assembled identical and homologous reads into clonotypes. Results of MiXCR analysis were further analyzed using tcR, an R package for TCR repertoire advanced data analysis. 30 Repertoire diversity (Shannon diversity and Shannon-Jensen Evenness and richness indexes) and gene usage were analyzed for V and J segments and for their combinations. Gene usage was analyzed on the level of normalized clone type proportions. The results were depicted according to IMGT nomenclature. 31 Sequencing depths were compared between patient groups and controls, respectively, and significance of different depths assessed by the Welch's t test followed by Bonferroni correction for multiplicity.
Comparing Patient Groups Regarding Clone Distributions and Abundances
Investigation of Clone Distributions
The following characteristics of combined V-J-clone distributions were analyzed using the Biodiversity R-package, 32 that is, Shannon index (H), entropy as of H 5 2 P p i logp i ; where p i depicts the proportion of V-J-element counts with number i in all V-J-element counts of the respective sample. The Shannon diversity qualifies both how many different clones could be found within a sample and how even these clones were represented. In addition, we calculated the Shannon-Jensen evenness (E) as of E 5 H=ln ðSÞ, in which S depicts the number of different V-J clones in each sample, also called clone richness, which was also reported. The Shannon-Jensen evenness specifically quantifies how even the clones are represented in the respective sample. 33 These tests were applied to the patient groups, including those with active disease (CC/LC/UC) and those in histopathological remission (CC-HR/LC-HR) or remission (UC-R), and were compared with patients with noninflamed colon regarded as control patients. Finally, the Welsh's t tests were applied to test for different mean values of these diversity measures between the different groups of samples compared with a statistical significance set at P # 0.05.
Investigation of Clone Abundances (Univariate Analysis)
The patient groups, including those with active disease (CC/ LC/UC) and those in histopathological remission (CC-HR/LC-HR) or remission (UC-R), were compared with patients with noninflamed colon regarded as control patients. Patients with active disease or in (histopathological) remission within the same disease groups were also compared with each other. To reveal TCRbV and bJ (TRBV-BJ) clones showing differences in abundance between 2 groups, we used univariate analyses. Hereto, we used a Wilcoxon rank-sum test with a significance level set at P # 0.05, as clone proportion distributions were highly skewed. All reported P values are descriptive, without having assessed multiplicity across all different comparisons shown in the Results section. False discovery rates (FDRs) were estimated according to the approach by Storey et al., 34 and are depicted in the Results section as q values set at q # 0.05.
Investigation of Clone Abundances (Multivariate Analysis)
To find discriminating patterns based on more than 1 clone, we used supervised multivariate analyses. Analysis of variable importance was run to select the most important TRBV-BJ clones differentiating among the groups. Because of many small nonzero values of importance for discrimination between all occurring TRBV-BJ clones, only the top 25 clones were picked as a robust result for further analysis. Regarding multivariate analysis, we used Sparse Partial Least Squares (sPLS) classification, 35 allowing for multivariate discriminative patterns in the respective comparison. We used a rigorous double cross-validation approach (leave-oneout cross validation [LOOCV] ) to optimize the number of latent variables used within sPLS (inner CV) and to determine hit rates on the left-out samples (outer CV). Finally, resampling P values were collected for 10,000 runs to assure significance of the observed hit rates. We further analyzed variable importance to characterize those TRBV-BJ clones responsible for the discrimination among the different groups under analysis. Variable importance was calculated as variable importance in projection (VIP) value, for each V-J-clone, in each group comparisons VIP ij 5 ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi ð of V-J-clone counts with number i in all V-J-clone counts of the respective sample, as above. w i gives the weight (importance) for this V-J-clone in component of j of the sPLS model. The VIP i as a measure of variable importance for the specific V-J-clone, is then calculated as the maximum of VIP ij across all components used in the model. 36 
RESULTS
To understand regional diversity of the TCRb repertoire of T cells, we focused on TCRbV-J regions using total RNA amplified by degenerate primers targeting all known TCRb chains. Patients with MC or UC were compared with noninflamed controls, as well as patients with MC in histopathological remission (CC/LC-HR) and patients with UC in clinical and histopathological remission (UC-R).
Comparisons of V-and J-Gene Segments of TCRb Chains Regarding Diversity, Evenness, and Richness
We first analyzed the diversity and distribution of the TRBV-J gene segments (evenness of TCRb clones) by assessing the CDR3 region, playing a paramount role in determining binding affinity and specificity of the receptors, by comparing Shannon diversity, Shannon-Jensen evenness, and richness indexes with a Welsh's 2-sample t test (Figs. 1-3 , descriptive P values reported in the figures). We observed a broad distribution of the diversity and evenness measures in the control samples (Figs.  1A, C, 2A, C, and 3A, B) . The TRBV-J combinations from patients with LC were significantly less diverse and less evenly distributed, as well as low in richness compared with controls (Fig. 1A) The diversity and the evenness of the LC clones were reduced compared with LC-HR clones albeit not significantly different because of significantly low clone richness (Fig. 1B) . However, patients with LC-HR did not show any significant changes either in diversity, evenness, or richness of TRBV-J clone distribution compared with controls (Fig. 1C) . Clone distributions in patients with LC were also significantly less diverse and less even, as well as low in richness compared with patients with CC (Fig. 1D) . In contrast, patients with CC and CC-HR did not reveal any significant differences in diversity, evenness, or richness compared with controls or compared with each other ( Fig. 2A-C) .
Compared with controls, both patients with UC and UC-R had significantly more diverse TRBV-J clones because of significantly increased richness, whereas no significant changes in their evenness (Fig. 3A, B) . However, a comparison between patients with UC and UC-R did not reveal any significant differences in TRBV-J diversity patterns (Fig. 3C) .
Sequencing depths were not homogenous across samples. groups. The sequencing depths were specific for the groups of UC, MC, and controls.
To detect the TCRb-V-J combinations discriminating between the disease groups and the controls, we used both univariate and supervised multivariate analyses based on the clone type proportions (Wilcoxon rank-sum test and sPLS classification). The results from univariate analysis are summarized in Table 3 . According to multivariate sPLS regression analysis, not all resampling results showed significance, but we anyhow report the most promising candidates, based on comparatively large hit rates (Table 4 ). Figure 4 displays the score plots for 1 comparison with a trend toward significance (P ¼ 0.06, LC vs LC-HR, Fig. 4C ), 2 comparisons with significance (P , 0.05, UC versus control, Fig 4H and UC-R versus control, Fig. 4I ), and nonsignificant results obtained. An sPLS discriminant analysis involving all disease groups, including controls, is depicted in Figure 5 . The score plots show how samples from the respective groups could be separated based on the first 2 sPLS clone components, which can be understood as clone signatures, i.e., linear combinations of the single clone profiles.
TCRb-V-J Combinations in Patients with LC
Univariate analysis of patients with LC patients revealed 69 clones different from controls, based on a 10% FDR cutoff, whereas the 5% FDR cutoff did not reveal any significance (Table 3 and see Table 1A , Supplemental Digital Content 2, http://links.lww.com/IBD/B499). Multivariate analysis showed that the most important TRBV-J combination by which patients with LC could be discriminated from noninflamed controls was the TRBV14-J2-5 clone, which had an 82% LOOCV hit rate (Table 4  and see Table 2A , Supplemental Digital Content 2, http://links.lww. com/IBD/B499). When we further scrutinized the results of univariate and multivariate analyses for the top 25 clones in this comparison, 12 clones were in common for these analyses (Fig. 6A , see Tables 1A, 2A , and 3A, Supplemental Digital Content 2, http:// links.lww.com/IBD/B499), in which TRBV14-J2-5 clone was detected as selective for patients with LC. Patients with LC compared with patients with LC-HR showed 75% LOOCV hit rates (P ¼ 0.06, Table 4 ), in which TRBV7-9-J2-3 showed the highest importance value (see Table 2B , Supplemental Digital Content 2, http:// links.lww.com/IBD/B499). Because of the low P value in multivariate approach, we further compared univariate and multivariate analyses which showed 11 common clones (Fig. 6A, see Tables  1B, 2B , and 3B, Supplemental Digital Content 2, http://links.lww. com/IBD/B499), suggesting TRBV7-9-J2-3 clone differential between patients with LC and LC-HR. Compared with controls, patients with LC-HR also showed a high LOOCV hit rate (77% ,  Table 4 ), which suggested TRBV10-3-J1-3, TRBV4-3-J1-5, and -J1-4 as important clones (see Table 2C , Supplemental Digital Content 2, http://links.lww.com/IBD/B499), whereas univariate analyses did not reveal any significant clones on 5% or 10% FDR (Table 3, see Table 1C , Supplemental Digital Content 2, http://links.lww.com/IBD/B499). Thus, univariate and multivariate analyses were not further compared.
Patients with LC were subsequently compared with patients with CC using univariate and multivariate analyses. The univariate analysis of patients with LC showed 86 clones significantly different from patients with CC (Table 3 and see Table 1D , Supplemental Digital Content 2, http://links.lww.com/IBD/B499), whereas multivariate analysis did not suggest discriminating clones detected due to only 63% LOO CV hit rates and no significance for the resampling P value (Table 4, see Table 2D , Supplemental Digital Content 2, http://links.lww.com/IBD/B499). On comparison between results of univariate and multivariate analyses of 25 top clones (Fig. 6A ), 8 clones common for both methods were found, in which TRBV10-3-J2-2, TRBV19-J2-2, and TRBV7-9-J1-1 were the most distinctive clones (see Tables 1D, 2D , and 3C, Supplemental Digital Content 2, http://links.lww.com/IBD/B499). These findings strengthen the importance of these clones as candidates for differentiating LC from CC immunopathology. Neither result from univariate nor multivariate analyses did reveal any significance for patients with CC to discriminate from noninflamed controls or patients with CC-HR (Table 3 and 4, see  Tables 1E-G 
TCRb-V-J Combinations in Patients with UC and UC Patients in Remission (UC-R)
Using univariate analysis, 160 clones differing from controls were detected in patients with UC (Table 3 and see  Table 1H , Supplemental Digital Content 2, http://links.lww. com/IBD/B499). Patients with UC could be discriminated from controls using multivariate analysis with a 79% LOOCV hit rate and a significant resampling P value (P ¼ 0.0045, Table 4 ). Examples for the most important clones for this discrimination were TRBV10-3-J1-2, TRBV4-2-J1-1, and TRBV4-3-J2-6 (see Table 2H , Supplemental Digital Content 2, http://links.lww. com/IBD/B499). Compared with controls, 16 clones were detected to discriminate patients with UC both by univariate and multivariate approaches (see Table 3D , Supplemental Digital Content 2, http://links.lww.com/IBD/B499), in which TRBV10-3-J1-2, TRBV4-2-J1-1, and TRBV4-3-J2-6 were also detected.
Similarly, patients with UC-R showed 122 different clones with significantly different prevalence compared with controls using univariate analysis (Table 3 and see Table 1I , Supplemental Digital Content 2, http://links.lww.com/IBD/B499). In addition, the comparison between controls and patients with UC-R using multivariate analysis showed an 84% LOOCV hit rate and a high resampling significance, P , 0.001 (Table 4) . Examples for the most important TRBV-J combinations include TRBV24-1-J1-2 and TRBV4-3-J2-3 (see Table 2I , Supplemental Digital Content 2, http://links.lww.com/IBD/B499). Comparison between univariate and multivariate analyses showed an overlap of 14 TRBV-J combinations including TRBV24-1-J1-2 and TRBV4-3-J2-3 (Fig.  6A , see Table 3E , Supplemental Digital Content 2, http://links. lww.com/IBD/B499). The comparison between patients with active UC and in remission (UC-R) did, however, not reveal any discriminating TRBV-J combinations in either of the analyses (see Tables 1J and 2J , Supplemental Digital Content 2, http:// links.lww.com/IBD/B499). Among patients with UC-R, 12 of them were treated with immunomodulatory agents and 7 were untreated at the time of the colonoscopy. According to univariate analysis, we did not observe any significant differences between treated and untreated patients with UC-R (see Table 1K , Supplemental Digital Content 2, http://links.lww.com/IBD/B499).
We also further analyzed the univariate results based on 5% FDR (q , 0.05, Fig. 6B ) with respect to overlap. Patients with UC and UC-R compared with controls showed a major overlap of 107 TRBV-J combinations (see Tables 1H and 1I , Supplemental Digital Content 2, http://links.lww.com/IBD/B499), whereas comparison of patients with LC to CC had less overlapping clones with other comparisons (Fig. 6B , see Table 1D , Supplemental Digital Content 2, http://links.lww.com/IBD/B499).
DISCUSSION
The pathophysiology of MC is still unclear, and the search for triggering factors and underlying dysfunctions in the mucosal immune system are still in an early stage. 1 To understand the nature of infiltrating T cells in MC immunopathology, we performed targeted NGS from colonic biopsies of patients with MC and UC compared with controls. For the first time, we analyzed and showed an oligoclonal TCRb distribution in patients with MC. Moreover, the diversity and evenness of the distribution of these clones were different between patients with CC and LC, as well as patients with UC. In addition, we were able to detect specific clones from TRBV-J gene segments to differentiate disease types (CC, LC, or UC) from controls and their remission counterparts (CC/LC-HR or UC-R). Altogether, our study further showed CC and LC as separate entities of MC, in which different T-cell clones were observed as part of the disease immunopathogenesis.
In this study, we focused on the TCRb chain, which is often preferred for analysis of the TCR repertoire due to the lower number of families despite a higher overall variability in sequences compared with the a chain. 37 During the analysis of the raw data, we found that approximately 50% of the D gene segments were detected, whereas the remaining segments were not classified. This has been reported on before and has been explained as extensive nibbling during recombination events, creating various D gene segments not yet classified and numerated. 30, 38 We thus focused on TCRb-V-J (TRBV-BJ) gene segment combinations. Previous studies have reported on oligoclonal TCRb distributions, [39] [40] [41] [42] especially in CD8 + LPLs, 43 in the healthy colon, which corresponds to our results from noninflamed control samples. Our results showed for the first time an oligoclonality in TCRb chains in patients with MC and in their histopathological remission counterparts (CC/LC-HR). Previous studies from our group have shown that both lamina propria and IELs have elevated expression of the proliferation marker Ki67 4,5 and reduced levels of TCR excision circles 6 in the colonic mucosa of patients with CC and LC, suggesting a local expansion of resident T cells rather than T-cell migration to the site of inflammation. The lower diversity with lower evenness and richness in the clonality of the TCRb chain in patients with LC compared with controls demonstrated in this study supports the interpretation of locally expanded clones in this patient group. Moreover, lower diversity due to lower richness in TCRb-V and J gene distribution in LC compared with patients with LC-HR suggest different T-cell responses depending on disease stage. Determining the numbers and types of clones differentiating between controls and patients with active disease (CC or LC) or in remission (CC/LC-HR) suggested different TRBV-J combinations for patients with LC and LC-HR, which may be important to understand the differences in T-cell infiltrations for the 2 disease states.
We observed differences in sequencing depths between the disease groups, which may lead to a similar pattern in richness of observed clones. The actual number of detected clones followed their richness for the comparisons of UC or UC-R patients with controls. Interestingly, comparing MC patients with controls, as well as for CC with LC samples, observed richness values did not follow our expectations based on their corresponding sequencing depths. Thus, the variations in the sequencing depth between the patient groups may stem from different amounts of infiltrating T cells.
The lack of significant TRBV-J clones from patients with CC or CC-HR indicate dysregulated immune responses due not only to T cells but also other infiltrating immune cells, e.g. eosinophils, neutrophils, or macrophages. 44 The differences between patients with CC and LC based on univariate analysis of TRBV-J clone usage may further support distinctive T-cell responses in the pathophysiology of these subtypes of MC.
A more oligoclonal character of the TCRb distribution as demonstrated by lower evenness and richness in LC compared with patients with CC indicates a more selective T-cell response in these patients toward certain antigen(s) as part of disease pathology. In addition, differences in the TCRb-V and J segments further support that CC and LC are 2 different entities with different etiologies. 5, 45 Despite similarities in the clinical symptoms of patients with CC and LC, patients with LC show a more intermittent disease course compared with patients with CC, 1 which might be due to differences in the T-cell responses and be mirrored by the more oligoclonal TCRb repertoire. Furthermore, patients with active disease could be differentiated from their counterparts in (histopathological) remission according to TCRb clone types. In support of this, we have reported on differences in their immunopathology in previous studies. 5, 44, 46, 47 In contrast to patients with MC, we have previously shown increased amounts of TCR excision circles-positive recent thymic emigrants in the colon of patients with UC, 48 which is in line with these results, showing oligoclonal TCRb usage with higher diversity due to higher richness in patients with UC and UC-R compared with controls. Similar to our results, several studies showed oligoclonal TCRb distribution in colonic mucosal biopsies of patients with UC [17] [18] [19] [20] and CD. 16, 49, 50 Moreover, CD8 + LPLs in UC 17 and CD4 + LPLs in CD 9, 11 were also shown as oligoclonal. However, some studies showed polyclonal TCRb distribution in the LPLs of patients with UC and CD, 51, 52 as well as FoxP3 + Tregs from LPLs in patients with UC. 53 To the best of our knowledge, there is hitherto no study investigating T-cell repertoires neither in MC, nor in patients with UC screening for all known TCRb-V and J segments using high-throughput sequencing.
Our results from patients with UC were similar to a previous study suggesting TRBV4 as an important clone, which was suggested to be due to long-term exposure to bacterial superantigens, such as streptococcal mitogenic exotoxin Z-2 (SMEZ-2). 18, 20 This suggestion might also be valid for patients with UC-R because of the lack of significant differences in TRBV clones, as well as similarities in TRBV clone (TRBV10-3 and 4-3) between patients with UC and UC-R. Another study focusing on patients with UC suggested selective expansion of CD8 + T cells expressing TRBV3-J1-6, 17,18 a clone that was not detected in our study population. This could be due to sequencing methodology, numbers of analyzed TRBV clones, or differences in study populations. 17, 18 A recent study identified 5 TCRb chain V gene segments (TRBV10-1, TRBV18, TRBV20-2, TRBV5-1, and TRBV7-2) more abundant in patients with CD if compared with samples from healthy controls. 16 Moreover, they detected a clone (TRBV10-1-J2-7) that correlated with disease severity in patients with CD, 16 which was not detected in any of the patient groups in our study. Moreover, 5 more TRBV-J clones identified in patients with CD 16 were found also in our study: TRBV7-2-J2-2 (patients with LC), V7-2-J2-4 (patients with LC, UC, and UC-R), V7-2-J2-7 (patients with LC), V18-J1-1 (patients with UC and UC-R), and V28-J1-1 (patients with LC), strengthening the likelihood that these clones are involved in the pathophysiology of all these inflammatory diseases of the colon.
The strengths of this study are the coverage of all 70 TRBV clones identified so far, simultaneous analysis of TRBV and BJ gene segments, and analyzing our data using modern technology: high-throughput NGS. One potential limitation is that TRBV-J clones were analyzed using whole colonic biopsies. As previous studies from our group have shown dominant CD8 + T infiltrations in the epithelium and the lamina propria, but reduced CD4 + T cells in the lamina propria in both patients with CC and LC, 4, 5, 44, 46 the results from this study are likely CD8 + T-cell oriented.
We applied both univariate and supervised multivariate approaches to find discriminating clones which characterize our patient groups. Some clones appeared to be important in multivariate analysis, but not so in our univariate approach. These clones might just appear in characteristic patterns consisting of more than a single clone, and, hence, do not appear in our univariate significant findings.
Currently, 186 TCRb chain sequences are published in the IMGT database (http://www.imgt.org/genedb/stats) and only very few have yet been associated with specific antigens in the database. 54 Despite ongoing research, TCRb-encoding sequences cannot yet be used to predict a corresponding antigen. Based on previous studies, various factors such as previous gastrointestinal infections, use of medications, or smoking were suggested as important etiological factors of MC. 1, 23 Thus, further studies are required to shed light on importance of these factors on TCRb distribution and clonality in vivo.
Altogether, our study showed an oligoclonal TCRb diversity in colonic biopsies from patients with MC and UC, which could be further separated by the usage of dominant TCRBV-J gene segments different from controls as well as their remission counterparts. These results are important in the understanding of the role of T-cell infiltration in MC immunopathology and contribute to the knowledge of MC immunopathology by suggesting selectively expanded T-cell clones in different disease stages.
